Clinical Trial Update: GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GLS-010 monotherapy to chemotherapy in relapsed or refractory classical Hodgkin's lymphoma is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• GLS-010

Snippet

Sponsor: Guangzhou Gloria Biosciences Co., Ltd. | Conditions: Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma | Phase 3 | Status: UNKNOWN